Fate Therapeutics IPO
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer treatment. The company focuses on iPSC-derived cell products and natural killer cell therapies. Investors follow Fate's clinical trial progress and its position in the competitive cell therapy and immuno-oncology markets.
What We Know
Fate Therapeutics went public in 2013 and has been trading on NASDAQ under ticker FATE. The company has raised additional capital through follow-on offerings to fund its clinical programs over the years. The stock has experienced significant volatility typical of clinical-stage biotech companies, with performance closely tied to trial results and pipeline developments. As a established public biotech company, Fate has built a substantial pipeline of iPSC-derived cellular immunotherapy candidates. Investors continue to monitor the company's clinical progress, regulatory interactions, and potential partnerships as it advances treatments through various stages of development.
Frequently Asked Questions
Has Fate Therapeutics had an IPO?
Yes, Fate Therapeutics completed its IPO in 2013 and has been publicly traded for over a decade. The company went public as a clinical-stage biotech.
When is the Fate Therapeutics IPO date?
Fate Therapeutics already went public in 2013, so there is no upcoming IPO. The company has been trading publicly for many years.
How can I buy Fate Therapeutics stock?
You can buy Fate Therapeutics stock through any brokerage account under ticker FATE. The company trades on NASDAQ and is readily available to investors.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts